Knightscope Turns Renewals into Revenue
Knightscope, Inc. (NASDAQ: KSCP) shares ---were flat nearing noon EST Monday. The company, an innovator in robotics and artificial intelligence technologies focused on public safety, has successfully secured renewals for 7 Autonomous Security Robots (ASRs) and extended Full Service Maintenance (FSM) agreements for 14 K1B clients with Emergency Communication Devices (ECDs), covering over 930 ECDs. These renewals collectively contribute more than $1 million in annual recurring revenue.Among the renewed agreements, Dignity Health has extended its Machine-as-a-Service (MaaS) subscription for an 8th consecutive year. Additionally, a Top 10 Fortune 500 entertainment corporation renewed its agreement for an 8th year, reinforcing its continued confidence in Knightscope’s technology. Westland, a residential community in Las Vegas, NV, also renewed its MaaS subscription, marking over four years of partnership with Knightscope.Further demonstrating growing market interest, a third independent analyst has initiated coverage of Knightscope’s stock. This latest initiation by Lake Street Capital Markets, alongside existing coverage from Ascendiant Capital Markets and H.C. Wainwright & Co., underscores the increasing recognition of Knightscope’s mission, technology, and market potential. KSCP shares poked ahead five cents to $10.89.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


